Tailored Communication to Reduce Cardiovascular Risk
|ClinicalTrials.gov Identifier: NCT01286311|
Recruitment Status : Completed
First Posted : January 31, 2011
Results First Posted : February 9, 2015
Last Update Posted : February 9, 2015
|Condition or disease||Intervention/treatment||Phase|
|Hypercholesterolemia Coronary Artery Disease Dyslipidemia Hypertension||Behavioral: Direct-to-patient tailored cardiovascular risk message system||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||464 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||Tailored Communication to Reduce Cardiovascular Risk|
|Study Start Date :||January 2011|
|Actual Primary Completion Date :||January 2013|
|Actual Study Completion Date :||January 2013|
Experimental: Direct-to-patient tailored cardiovascular risk message system
Eligible patients cared for by physicians randomized to the active intervention group will be mailed a tailored cardiovascular risk message.
Behavioral: Direct-to-patient tailored cardiovascular risk message system
Patient informational mailings
|No Intervention: Control|
- Comparative Outcomes: Intervention Group LDL Reduction Compared to Control Group LDL Reduction [ Time Frame: 9 months ]Significant LDL cholesterol reduction at 9 months Definition: Percentage of patients with LDL-C repeated and which is at least 30 mg/dl lower than baseline
- Frequency of Clinical Encounters [ Time Frame: 9 months ]This will measure the difference in frequency of clinical encounters in the electronic medical record.
- Medication Prescriptions for Dyslipidemia [ Time Frame: 9 months ]This will look at whether lipid lowering medications (LLM) were prescribed for dyslipidemia.
- Percentage of Patients With Uncontrolled Hypertension Who Had an Increase in the Number of Antihypertensive Medication Drug Classes Prescribed [ Time Frame: 9 months ]This will measure the percentage of participants who had uncontrolled hypertension at baseline who had an increase in the number of antihypertensive medication drug classes prescribed within 9 months.
- Presence of an Aspirin Prescription [ Time Frame: 9 months ]This will measure the presence of an aspirin prescriptions on the medication list in the electronic medical record.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01286311
|United States, Illinois|
|Northwestern Medical Faculty Foundation General Internal Medicine Ambulatory Clinic|
|Chicago, Illinois, United States, 60611|
|Principal Investigator:||Stephen Persell, MD, MPH||Northwestern University Division of General Internal Medicine, Feinberg School of Medicine and Institute for Healthcare Studies|